乔颖;李华芳;

• 1:上海交通大学医学院附属精神卫生中心药物临床试验机构

摘要(Abstract)：

代谢组学是基础生物学的一个组成部分,能从总体水平上反映机体的代谢途径。代谢组学通过识别生物标记物来体现机体在疾病状况下的病理变化,并监测机体对治疗的应答,为医疗实践提供重要依据。精神障碍与多种神经递质、脂肪酸以及线粒体功能的代谢途径受干扰有关。代谢组学能详细地描记受到扰动的生化途径和链接在这些途径中能够反映疾病特征的关键性生物标记物。本文阐述了代谢组学的概念、相关技术及精神障碍的代谢组学研究进展。

关键词(KeyWords)： 代谢组学;精神分裂症;重性抑郁症;双相情感障碍;神经症

Abstract:

Keywords:

基金项目(Foundation): 科技重大专项“精神药物新药临床评价研究技术平台”(编号2012ZX09303-003);; 上海市优秀人才培养课题(编号XBR2011049)

作者(Author): 乔颖;李华芳;

Email:

DOI: 10.19577/j.cnki.issn10074406.2013.02.019

参考文献(References)：

• [1]German JB,Gillies LA,Smilowitz JT,et al.Lipidomics and lipid profiling in metabolomics[J].Curr Opin Lipidol,2007,18(1):66.
• [2]许国旺,路鑫,杨胜利.代谢组学研究进展[J].中国医学科学院学报,2007,29(6):701.
• [3]隆琦,陈楠.代谢组学在疾病中的应用进展[J].医学综述,2010,16(9):1300.
• [4]Abel L.Handbook of Neurochemistry and Molecular Neurobiology[M].3rd Edition.New York:Springer,2007:889-912.
• [5]Kristal BS,Shurubor YI,Kaddurah-Daouk R,et al.High-performance liquid chromatography separations coupled with coulometric electrode array detectors:a unique approach to metabolomics[J].Methods Mol Biol,2007,358:159.
• [6]Tweeddale H,Notley-McRobb L,Ferenci T.Effect of slow growth on metabolism of Escherichia coli,as revealed by global metabolite pool"(metabolome)"analysis[J].J Bacterid,1998,180(19):5109.
• [7]Nicholson JK,Lindon JC,Holmes E.'Metabonomics*:understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J].Xenobiotica,1999,29(11):1181.
• [8]Fiehn O,Kopka J,Dormann P,et al.Metabolite profiling for plant functional genomics[J].Nat Biotechnol,2000,18(11):1157.
• [9]王斯婷,李晓娜,王皎,等.代谢组学及其分析技术[J].药物分析杂志,2010,30(9):1792.
• [10]Holmes E,Tang HR,Wang YL,et al,The assessment of plant metabolite profiles by NMR-based methodologies[J].Plant Med,2006,72(9):771.
• [11]Dumas ME,Wilder SP,Bihoreau MT,et al.Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models[J].Nat Genet,2007,39(5):666.
• [12]Holmes E,Wilson ID,Nicholson JK.Metabolic phenotyping in health and disease[J].Cell,2008,134(5):714.
• [13]Patterson AD,Li H,Eichler GS,et al.UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as took for understanding the cellular response to ionizing radiation[J].Anal Chem,2008,80(3):665.
• [14]Dettmer K,Aronov PA,Hammock BD,et al.Mass spectrometry-based metabolomics[J].Mass Spectrom Rev,2007,26(1):51.
• [15]Lee S,Tsang A,Huang YQ,et al.The epidemiology of depression in metropolitan China[J].Psychol Med,2009,39(5):735.
• [16]Kessler RC,Berglund P,Demler O,et al.The epidemiology of major depressive disorder:results from the National Comorbidity Survey Replication(NCS-R)[J].JAMA.2003,289(23):3095.
• [17]Zheng P,Gao HC,Li Q,et al.Plasma metabonomics as a novel diagnostic approach for major depressive disorder[J].J Proteome Res,??2012,11(3):1741.
• [18]Paige LA,Mitchell MW,Krishnan KR,et al.A preliminary metabolomic analysis of older adults with and without depression[J].Int J Geriatr Psychiatry,2007,22(5):418.
• [19]Ji Y,Hebbring S,Zhu H,et al.Glycine and a glycine dehydrogenase(GLDC)SNP as citalopram/escitalopram response biomarkers in depression:pharmacometabolomics-informed pharmacogenomics[J].Clin Pharmacol Ther,2011,89(1):97.
• [20]Kaddurah-Daouk R,Yuan P,Boyle SH,et al.Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile[J].Sci Rep,2012,2:667.
• [21]Kaddurah-Daouk R,Boyle SH,Matson W,et al.Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients:a proof of concept[J].Transl Psychiatry,2011,1.pii:e26.
• [22]Huang JT,Leweke FM,Tsang TM,et al.CSF metabolic and proteomic profiles in patients prodromal for psychosis[J].PLoS One,2007,2(8):e756.
• [23]Oresic M,Tang J,Sepp(a|¨)nen-Laakso T,et al.Metabolome in schizophrenia and other psychotic disorders:a general population-based study[J].Genome Med,2011,3(3):19.
• [24]Kaddurah-Daouk R,McEvoy J,Baillie RA,et al.Metabolomic mapping of atypical antipsychotic effects in schizophrenia[J].Mol Psychiatry,2007,12(10):934.
• [25]Kaddurah-Daouk R,Krishnan KR.Metabolomics:a global biochemical approach to the study of central nervous system diseases[J].Neuropsy-chopharmacol,2009,34(1):173.
• [26]Condray R,Keshavan MS,Reddy RD,et al.3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia[J].Int J Neuropsychopharmacol,2011,14(6):756.
• [27]He Y,Yu Z,Giegling I,et al.Schizophrenia shows a unique metabolomics signature in plasma[J].Transl psychiatry,2012,2:e149.
• [28]Atmaca M,Kuloglu M,Tezcan E,et al.Serum leptin and cholesterol levels in patients with bipolar disorder[J].Neuropsychobiology,2002,46(4):176.
• [29]Schwarz E,Prabakaran S,Whitfield P,et al.High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids,phosphatidylcholines,and ceramides[J].J Proteome Res,2008,7(10):4266.
• [30]Lan MJ,McLoughlin GA,Griffin JL,et al.Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder[J].Mol Psychiatry,2009,14(3):269.
• [31]Filiou MD,Zhang Y,Teplytska L,et al.Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways[J].Biol Psychiatry,2011,70(11):1074.
• [32]Zhang Y,Filiou MD,Reckow S,et al.Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways[J].Mol Cell Proteomics,2011,10(12):M111.008110.
• [33]Leuchter AF,Cook IA,Hamilton SP.Biomarkers to predict antidepressant response[J].Curr Psychiatry Rep,2010,12(6):553.